ANTI-CANCER DRUGS

简称 ANTI-CANCER DRUG ·UNITED STATES ·出版周期 Monthly ·年均收录 131 篇

2.2

最新影响因子

2.10%

自引率

容易

投稿难度

偏慢,4-8周

审稿周期

期刊简介

ANTI-CANCER DRUGS是一本专注于抗癌药物研究的国际期刊，ISSN号为0959-4973，由Lippincott Williams & Wilkins出版，出版地为英国，出版周期为月刊。该期刊的影响因子根据年份有所不同，近年保持在2-3左右，属于SCI收录期刊，但并非开放获取（OA）期刊，中科院分区通常位于医学或药学领域的3区或4区。该杂志的发文特点集中于抗癌药物的临床前和临床研究，涵盖药物开发、药理学、分子机制及治疗应用等领域，尤其关注新型抗癌药物的实验与临床评估。杂志的质量在抗癌药物研究领域具有一定认可度，但由于影响因子中等且竞争激烈，投稿需注意研究创新性和数据完整性，可能存在审稿周期较长或接收率较低的风险。总体而言，该期刊适合专注于抗癌药物研究的学者投稿，但需结合自身研究水平选择合适的发表平台。

影响因子趋势

近期发表

Anlotinib inhibits glioma cell proliferation, migration, and invasion by suppressing c-MET/AKT/mTOR signaling and altering autophagy-associated protein expression 2026-09-03

Prophylactic tramadol for oxaliplatin-induced peripheral vascular pain: a single-arm retrospective study 2026-08-30

MLN4924 suppresses pancreatic cancer progression and enhances chemosensitivity to gemcitabine by targeting the PTGS2/EGFR–PI3K/Akt/mTOR signaling axis 2026-08-14

Capecitabine-induced pneumonitis: a rare case report and literature review 2026-08-30

Clinical ethics in oncology 2026-08-08

Tertiary lymphoid structure transcriptomic signatures show limited and cohort-dependent value for predicting axillary nodal involvement in oestrogen receptor-positive luminal breast cancer 2026-08-02

The PITX2/CKMT1B axis promotes lung adenocarcinoma stemness via lipid accumulation 2026-01-17

Synergistic antitumor effect between Olaparib and Chidamide by regulation of MYBL2 in lung cancer 2026-05-02

The future of cancer treatment: integrating science, technology, and global collaboration 2026-07-10

Akt inhibitor-IV in estrogen receptor-positive breast cancer cells: cytotoxic, apoptotic, transcriptional, and in-silico comparison with tamoxifen 2026-07-02